Dopamine on top of standard treatment for patients with exacerbation of Heart Failure, at home situation

Dopamine on top of standard treatment for patients with exacerbation of Heart Failure, at home situation - Do-HF

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35847

Enrollment

110

Registered

2011-06-10

Start date

2011-11-29

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure heart failure

Interventions

Patients who are randomized to Dopamine will get a Dopamine infusion during 24 hours +- 6 hr.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Exacerbation heart failure with NYHA class III-IV

Exclusion criteria

Exclusion criteria: Cardiogenic shock Tachycardia, heart rate > 100 bpm Indication for hospitalization Severe aortic valve stenosis Severe hepatic or renal disease Patients with acute coronary syndromes Previous participation in the study Life expectancy of

Design outcomes

Primary

Measure	Time frame
• Unplanned hospital admission for Heart Failure	—

Secondary

Measure	Time frame
• Weight reduction • Renal impairment (elevation in serum creatinine by more than 40 micromoles/L) • Pro-BNP level • Absolute need of inotropicum • Occurrence of arrhythmia, hypertension, anginal pain, nausea, vomiting, and headache • Pharmacy-economical efficiency of the treatment Galectin-3 value	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)